As the head of product development for the Janssen Human Microbiome Institute (JHMI), Dan Meyers works closely with internal and external collaborators to drive unique microbiome product development strategies. Dan joined the JHMI from the Novartis Institutes of Biomedical Research (NIBR), where he was a senior translation medicine expert, chairman of NIBR’s
protocol review committee, and member of the first-in-human safety committee. During his decade plus time at NIBR, Dan gained an expertise in bringing medicines from the earliest stages of preclinical research and through late-stage
clinical development. As a project leader, he led teams to successfully file investigational new drug applications and clinical trial applications, and has planned and executed over 25 clinical studies including multiple first-in-human, proof-ofconcept, mechanistic profiling and clinical pharmacology studies for both small and large molecules. He was also a core member of a late-stage development team which progressed a novel drug through Phase 2 and Phase 3 programs.
Prior to joining NIBR, Dan spent the first few years of his career as a physician scientist at the Veteran Affairs Medical Center in Long Beach, California, where he conducted basic and clinical research and cared for patients in the endocrinology and lipid clinics. Dan holds a Bachelor of Science Degree in microbiology from Brigham Young University
and a M.D. from The University of Washington in Seattle. He completed his internal medicine residency at the University of Utah, followed by a clinical and research fellowship in endocrinology, metabolism and nutrition at the University of Washington.